$ALNY News

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Strong Alignment with the Little Book That Makes You Rich Growth Strategy

Are Options Traders Betting on a Big Move in Alnylam Stock?

If You Invested $100 In Alnylam Pharmaceuticals Stock 10 Years Ago, You Would Have This Much Today

Alnylam Issues 2025 Corporate Responsibility Report

Citigroup Initiates Coverage On Alnylam Pharmaceuticals with Buy Rating, Announces Price Target of $380

How Investors Are Reacting To Alnylam Pharmaceuticals (ALNY) New HELIOS-B Vutrisiran Data And Real-World Study

Alnylam’s Vutrisiran Data And Real-World Study Contrast With Depressed Valuation

Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build

Morgan Stanley Increases Price Goal on Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

Alnylam Presents HELIOS-B Data At Heart Failure 2026 Supporting Vutrisiran As First-Line Treatment Across Broad ATTR-CM Populations

A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness

Alnylam to Webcast Presentations at Upcoming Investor Conferences

Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $510 Price Target

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

Alnylam Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth